Reply to thread

Message

<blockquote data-quote="BBinger" data-source="post: 1272447" data-attributes="member: 9217">I suspect the marijuana legalization train is a long term threat to psychiatric pharma cash cows. Psych drugs and cannabis compete for the numerous patients whose complaint takes the form &quot;I'm miserable, and I care deeply about it.&quot; Psych drugs attack either part of that complaint with varying degrees of efficacy. Cannabis attacks the caring about it with a high degree of efficacy.Companies working on the recreational to therapeutic niche tend to see their products hit with profound regulatory handicaps in the US. Yes, one firm got approval to market the S enantiomer of Ketamine approved for MDD, but to receive esketamine the patients have to go to an office to have it administered ensuring it will never be popular in the way blockbusters like Prozac, valproate, or Seroquel were.If you are comfortable with the risk, keep going but do follow the news. If the Phase 3 trials are good (very probable), you may want to exit your position before approval which will likely come with absolutely oppressive rules for prescribers.</blockquote>

[QUOTE="BBinger, post: 1272447, member: 9217"] I suspect the marijuana legalization train is a long term threat to psychiatric pharma cash cows. Psych drugs and cannabis compete for the numerous patients whose complaint takes the form "I'm miserable, and I care deeply about it." Psych drugs attack either part of that complaint with varying degrees of efficacy. Cannabis attacks the caring about it with a high degree of efficacy. Companies working on the recreational to therapeutic niche tend to see their products hit with profound regulatory handicaps in the US. Yes, one firm got approval to market the S enantiomer of Ketamine approved for MDD, but to receive esketamine the patients have to go to an office to have it administered ensuring it will never be popular in the way blockbusters like Prozac, valproate, or Seroquel were. If you are comfortable with the risk, keep going but do follow the news. If the Phase 3 trials are good (very probable), you may want to exit your position before approval which will likely come with absolutely oppressive rules for prescribers. [/QUOTE]

Verification